drugset / Trial / NCT06702098
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
Phase 0
Not yet recruiting
10 enrolled
Guangzhou Ruixin Biotechnological Co., LTD
Fifth Affiliated Hospital of Guangzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
Timeline
- Start
- 2024-11-25
- Primary completion
- 2026-08-31
- Completion
- 2026-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iNK cells | Cell therapy | 1e+09 cells | Intravenous |